INKT
MiNK Therapeutics Inc

1,727
Mkt Cap
$51.73M
Volume
31,875.00
52W High
$76.00
52W Low
$4.56
PE Ratio
-3.63
INKT Fundamentals
Price
$10.88
Prev Close
$11.02
Open
$11.00
50D MA
$14.09
Beta
0.55
Avg. Volume
27,747.74
EPS (Annual)
-$2.86
P/B
-3.75
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Expectations By $0.21 EPS
MiNK Therapeutics (NASDAQ:INKT - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Analysts Offer Predictions for INKT Q1 Earnings
MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for MiNK Therapeutics in a research note issued on...
MarketBeat·11d ago
News Placeholder
New Strong Sell Stocks for August 22nd
INKT, MNR and CSIQ have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2025.
Zacks·3mo ago
News Placeholder
MiNK Therapeutics stock falls after William Blair downgrade
Investing.com -- MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.
investing.com·4mo ago
News Placeholder
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy
“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.
Stocktwits·4mo ago
News Placeholder
Why MiNK Therapeutics Stock Is Up 11% Monday
MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. read more...
Benzinga·2y ago
News Placeholder
HC Wainwright Lowers MiNK Therapeutics (NASDAQ:INKT) Price Target to $9.00
MiNK Therapeutics (NASDAQ:INKT Free Report) had its target price reduced by HC Wainwright from $10.00 to $9.00 in a report released on Thursday morning, Benzinga reports. They currently have...
Zolmax·2y ago
News Placeholder
Q4 2023 Mink Therapeutics Inc Earnings Call Transcript
Related Stocks: NAS:INKT...
GuruFocus·2y ago
News Placeholder
MiNK Reports Fourth Quarter and Year-End 2023 Results
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development...
Globe Newswire·2y ago
News Placeholder
Earnings Outlook For MiNK Therapeutics
read more...
Benzinga·2y ago

Latest INKT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.